Kent Chak-Yu So, Krissada Meemook, Jianqiang Xu, Chun-Chin Chang, Tawai Ngernsritrakul, Surakiat Leelasithorn, Ching-Wei Lee, Angel Lai, Kevin Ka-Ho Kam, Bryan P Yan, Alex Pui-Wai Lee, Adam S H Sung, Yat-Yin Lam
{"title":"亚洲三尖瓣经导管边缘到边缘修复的初步实际经验。","authors":"Kent Chak-Yu So, Krissada Meemook, Jianqiang Xu, Chun-Chin Chang, Tawai Ngernsritrakul, Surakiat Leelasithorn, Ching-Wei Lee, Angel Lai, Kevin Ka-Ho Kam, Bryan P Yan, Alex Pui-Wai Lee, Adam S H Sung, Yat-Yin Lam","doi":"10.1016/j.jacasi.2025.07.024","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Tricuspid regurgitation (TR) causes significant morbidity. Transcatheter edge-to-edge repair (TEER) has been proven effective in relieving TR symptoms. Access to tricuspid TEER and the associated experience are limited in Asia.</p><p><strong>Objectives: </strong>This study aimed to summarize the initial experience with the tricuspid TEER system (Abbott) in Asia.</p><p><strong>Methods: </strong>Patients undergoing tricuspid TEER (Abbott) from 2017 to 2024 were enrolled from 4 centers in Asia. The primary endpoint was device success (TR ≤moderate) at 30 days. Secondary endpoints included inpatient complications, 30-day NYHA functional class, and 30-day major adverse events. Risk factors for 30-day device success were identified.</p><p><strong>Results: </strong>A total of 106 patients were included, with a mean age of 76.1 ± 10 years, and 88.7% (n = 94 of 106) had atrial fibrillation. Most TR cases treated were functional (88.7% [n = 94 of 106]), with over half classified as massive or torrential (56.6% [n = 60 of 106]). Tricuspid TEER was performed using off-label MitraClip in 22.6% (n = 24), while the remaining 77.4% (n = 82) utilized TriClip. Combined procedures (with mitral TEER and others) were common (47.2% [n = 50 of 106]). At 30 days, 74.0% (n = 77 of 104) achieved device success (TR ≤moderate), and 95.2% (n = 99 of 104) experienced at least a 1-grade TR reduction. Additionally, 96.2% (n = 100 of 104) were NYHA functional class I/II, and major adverse events were 1.9% (n = 2 of 106) at 30 days. Baseline nontorrential TR and increased clinical experience (second half of cases) were associated with 30-day device success (P = 0.010 and P = 0.044, respectively).</p><p><strong>Conclusions: </strong>The early experience with tricuspid TEER in Asia is promising, demonstrating a reasonable device success rate and a high safety profile. Clinical experience is associated with improved device success.</p>","PeriodicalId":73529,"journal":{"name":"JACC. Asia","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Initial Real-World Experience of Tricuspid Transcatheter Edge-to-Edge Repair in Asia.\",\"authors\":\"Kent Chak-Yu So, Krissada Meemook, Jianqiang Xu, Chun-Chin Chang, Tawai Ngernsritrakul, Surakiat Leelasithorn, Ching-Wei Lee, Angel Lai, Kevin Ka-Ho Kam, Bryan P Yan, Alex Pui-Wai Lee, Adam S H Sung, Yat-Yin Lam\",\"doi\":\"10.1016/j.jacasi.2025.07.024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Tricuspid regurgitation (TR) causes significant morbidity. Transcatheter edge-to-edge repair (TEER) has been proven effective in relieving TR symptoms. Access to tricuspid TEER and the associated experience are limited in Asia.</p><p><strong>Objectives: </strong>This study aimed to summarize the initial experience with the tricuspid TEER system (Abbott) in Asia.</p><p><strong>Methods: </strong>Patients undergoing tricuspid TEER (Abbott) from 2017 to 2024 were enrolled from 4 centers in Asia. The primary endpoint was device success (TR ≤moderate) at 30 days. Secondary endpoints included inpatient complications, 30-day NYHA functional class, and 30-day major adverse events. Risk factors for 30-day device success were identified.</p><p><strong>Results: </strong>A total of 106 patients were included, with a mean age of 76.1 ± 10 years, and 88.7% (n = 94 of 106) had atrial fibrillation. Most TR cases treated were functional (88.7% [n = 94 of 106]), with over half classified as massive or torrential (56.6% [n = 60 of 106]). Tricuspid TEER was performed using off-label MitraClip in 22.6% (n = 24), while the remaining 77.4% (n = 82) utilized TriClip. Combined procedures (with mitral TEER and others) were common (47.2% [n = 50 of 106]). At 30 days, 74.0% (n = 77 of 104) achieved device success (TR ≤moderate), and 95.2% (n = 99 of 104) experienced at least a 1-grade TR reduction. Additionally, 96.2% (n = 100 of 104) were NYHA functional class I/II, and major adverse events were 1.9% (n = 2 of 106) at 30 days. Baseline nontorrential TR and increased clinical experience (second half of cases) were associated with 30-day device success (P = 0.010 and P = 0.044, respectively).</p><p><strong>Conclusions: </strong>The early experience with tricuspid TEER in Asia is promising, demonstrating a reasonable device success rate and a high safety profile. Clinical experience is associated with improved device success.</p>\",\"PeriodicalId\":73529,\"journal\":{\"name\":\"JACC. Asia\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JACC. Asia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jacasi.2025.07.024\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Asia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jacasi.2025.07.024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Initial Real-World Experience of Tricuspid Transcatheter Edge-to-Edge Repair in Asia.
Background: Tricuspid regurgitation (TR) causes significant morbidity. Transcatheter edge-to-edge repair (TEER) has been proven effective in relieving TR symptoms. Access to tricuspid TEER and the associated experience are limited in Asia.
Objectives: This study aimed to summarize the initial experience with the tricuspid TEER system (Abbott) in Asia.
Methods: Patients undergoing tricuspid TEER (Abbott) from 2017 to 2024 were enrolled from 4 centers in Asia. The primary endpoint was device success (TR ≤moderate) at 30 days. Secondary endpoints included inpatient complications, 30-day NYHA functional class, and 30-day major adverse events. Risk factors for 30-day device success were identified.
Results: A total of 106 patients were included, with a mean age of 76.1 ± 10 years, and 88.7% (n = 94 of 106) had atrial fibrillation. Most TR cases treated were functional (88.7% [n = 94 of 106]), with over half classified as massive or torrential (56.6% [n = 60 of 106]). Tricuspid TEER was performed using off-label MitraClip in 22.6% (n = 24), while the remaining 77.4% (n = 82) utilized TriClip. Combined procedures (with mitral TEER and others) were common (47.2% [n = 50 of 106]). At 30 days, 74.0% (n = 77 of 104) achieved device success (TR ≤moderate), and 95.2% (n = 99 of 104) experienced at least a 1-grade TR reduction. Additionally, 96.2% (n = 100 of 104) were NYHA functional class I/II, and major adverse events were 1.9% (n = 2 of 106) at 30 days. Baseline nontorrential TR and increased clinical experience (second half of cases) were associated with 30-day device success (P = 0.010 and P = 0.044, respectively).
Conclusions: The early experience with tricuspid TEER in Asia is promising, demonstrating a reasonable device success rate and a high safety profile. Clinical experience is associated with improved device success.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
